Allergy Clinical Trial
Official title:
A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)
Verified date | November 2014 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.
Status | Completed |
Enrollment | 203 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Subject must be 50 years of age or older, of either sex, and of any race/ethnicity. - Subject must have a clinical history of ragweed-induced allergic rhinoconjunctivitis with or without asthma. - Subject must have a positive skin prick test response to Ambrosia artemisiifolia at the Screening Visit - Subject must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at the Screening Visit and at Randomization. - A subject's clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator. Exclusion Criteria: - Subject with asthma who requires inhaled corticosteroids for the treatment of their asthma during the study period. - Subject requiring anti-allergy medications during the time period from randomization to study completion. - Subject who has received an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms). - Subject with a history of anaphylaxis with cardiorespiratory symptoms. - Subject with a history of chronic urticaria or angioedema. - Subject with current severe atopic dermatitis. - Female subject who is breastfeeding, pregnant, or intending to become pregnant. - Subject with a history of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine. - Subject with a history of self-injectable epinephrine use. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Proportion of Participants Reporting Treatment-emergent Adverse Events (AEs) | Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with treatment-emergent AEs were recorded. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs are new AEs that occur after participants have been randomized into the trial, or existing AEs that occurred during Screening that increase in severity after randomization. | Up to Day 42 | Yes |
Secondary | Proportion of Participants Reporting Oral Pruritus | Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with oral pruritus were reported. | Up to Day 42 | Yes |
Secondary | Proportion of Participants Reporting Ear Pruritus | Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with ear pruritus were reported. | Up to Day 42 | Yes |
Secondary | Proportion of Participants Reporting Throat Irritation | Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with throat irritation were reported. | Up to Day 42 | Yes |
Secondary | Proportion of Participants Reporting Mouth Oedema | Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with mouth oedema were reported. | Up to Day 42 | Yes |
Secondary | Proportion of Participants Who Discontinued Due to Adverse Events. | Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with AEs leading to study discontinuation were reported. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. | Up to Day 28 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02032056 -
Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period
|
N/A | |
Completed |
NCT01842711 -
Cumulative Irritation Patch Test
|
N/A | |
Completed |
NCT01633840 -
New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges
|
N/A | |
Completed |
NCT00997971 -
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
|
Phase 3 | |
Completed |
NCT00554983 -
Efficacy and Safety From a Recombinant Folding Variant of Bet v 1
|
Phase 3 | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00220753 -
Air Cleaners for Children and Adolescents With Asthma and Dog Allergy
|
N/A | |
Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
Completed |
NCT04126096 -
Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
|
N/A | |
Completed |
NCT04046731 -
Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation
|
N/A | |
Completed |
NCT04004351 -
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
|
||
Not yet recruiting |
NCT05997784 -
Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
|
||
Completed |
NCT04418999 -
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
|
Early Phase 1 | |
Completed |
NCT04186949 -
Early Origins of Allergy and Asthma
|
||
Completed |
NCT02127801 -
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT05011071 -
The Alberta BLOOM Premature Child Study
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT02306473 -
The Leaky Lung Test
|
Early Phase 1 | |
Completed |
NCT02596321 -
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
|
Phase 3 | |
Terminated |
NCT02601690 -
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
|